[Brain Cells. Photo Credit to Pixabay] 

On August 26, 2026, the U.S. Food and Drug Administration approved daraxonrasib, a new targeted treatment for metastatic pancreatic cancer, following a Phase 3 trial that nearly doubled median overall survival compared with standard chemotherapy.

Daraxonrasib, sold under the brand name Rasonque, was approved for adults with metastatic pancreatic adenocarcinoma who had received at least one previous systemic therapy or were not candidates for multiagent systemic therapy. The approval is particularly significant because pancreatic cancer remains one of the hardest cancers to treat. 

Its five-year relative survival rate stands at only about 14 percent, and symptoms may not appear until the cancer has already grown or spread.

By the time pancreatic cancer is diagnosed, treatment options may already be limited, which makes the development of new therapies especially important.

More than 90 percent of pancreatic ductal adenocarcinomas contain mutations that activate proteins in the RAS family, most commonly the KRAS.

RAS proteins act somewhat like switches inside cells, helping regulate cell growth.

When certain mutations occur, RAS can become stuck in its active, or “ON,” state and continue sending signals that encourage cancer cells to multiply uncontrollably.

Scientists have known for decades that RAS plays a significant role in cancer, but directly targeting it has been extremely challenging because the protein has few clear spaces where traditional drugs can easily bind.

Due to this challenge, RAS was once considered one of the most difficult cancer targets to treat with drugs.

Daraxonrasib was developed as a RAS(ON) multiselective inhibitor, targeting several forms of RAS while the protein is active and reducing signals that help cancer cells grow.

Originally studied under the research name RMC-6236, early Phase 1/1b results presented in 2023 provided the first indications of its potential in pancreatic cancer.

Among 46 evaluable patients, approximately 20 percent had an objective tumor response, but the study was still too small to determine whether the drug could extend survival.

These early results were encouraging, but researchers needed more patients and longer follow-up to determine whether the treatment could provide a meaningful benefit.

Stronger evidence emerged in May 2026, when Phase 1–2 results involving 168 previously treated patients with RAS-mutated pancreatic cancer were published in The New England Journal of Medicine.

Researchers selected 300 milligrams once daily for Phase 3 testing, and among a subgroup of 26 second-line patients with RAS G12 mutations who received this dose, 35 percent had an objective tumor response, with a median progression-free survival of 8.5 months and median overall survival of 13.1 months.

Despite these promising initial results, researchers still needed a larger randomized trial to determine whether daraxonrasib was actually better than existing chemotherapy.

The Phase 3 RASolute 302 trial enrolled 500 patients with previously treated metastatic pancreatic adenocarcinoma and randomly assigned them to receive either daraxonrasib or standard chemotherapy.

The results showed a clear benefit: median overall survival was 13.2 months with daraxonrasib compared with 6.7 months with chemotherapy, while median progression-free survival was 7.2 months compared with 3.6 months.

The objective response rate was also significantly higher, at 30 percent with daraxonrasib compared with 11 percent with chemotherapy.

Based on these promising results, the FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who had received at least one previous systemic treatment or were not candidates for multiagent systemic therapy.

However, stating that the drug “nearly doubled survival” does not mean that daraxonrasib cures pancreatic cancer or that every patient will live twice as long.

Median overall survival refers to the point at which half of the patients in a study are still alive, so individual outcomes can vary widely.

Daraxonrasib can also cause side effects such as rash, diarrhea, nausea, fatigue, and vomiting, while the FDA warns about less common but more serious complications.

The Phase 3 trial mainly focused on patients whose metastatic cancer had already been treated, so the results cannot automatically be applied to every pancreatic cancer patient.

Researchers also need to determine how long the benefits of RAS inhibition can last and whether cancer cells may eventually develop resistance.

Understanding resistance will be important because cancer cells can evolve over time and may find new ways to continue growing despite treatment.

Still, daraxonrasib shows how cancer treatment can evolve when scientists find a way to target a protein that once seemed almost impossible to reach.

What began as early signs of activity in 2023 eventually led to stronger Phase 1–2 findings, a large Phase 3 trial, and FDA approval.

For patients facing one of the most challenging cancers, a few additional months of survival can be meaningful, and the scientific impact may extend beyond pancreatic cancer because RAS mutations are also found in other cancers.

Could targeting RAS eventually change the outlook for pancreatic cancer and other RAS-driven cancers?